Respiratory medicine · 2026
Exploring the relationship between adherence and outcomes in pulmonary arterial hypertension: A retrospective cohort study in the United States.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Marco Teresa, Paoli Carly J, Germack Hayley D, Croteau Nicole S, Simeone Jason C, Tang Fei, Doad Gurinderpal, Panjabi Sumeet, Farber Harrison
Аннотация
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive disease with significant morbidity and mortality. New medications have improved outcomes, but adherence is crucial.
OBJECTIVE: Exploring adherence to PAH-specific therapies across therapeutic classes, we identified factors associated with non-adherence and evaluated its impact on clinical outcomes.
METHODS: Using claims from the Komodo Research Database, we identified patients initiating therapy with phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) stimulators, or prostacyclin pathway agents (PPA) between January 2017 and June 2022. Adherence was measured by proportion of days covered (PDC) during the treatment period, defined as 60 days after first therapy until treatment discontinuation/censor. Non-adherence was defined as PDC <80 %. Clinical outcomes were assessed during the treatment period. Stepwise Cox proportional-hazard models identified predictors of non-adherence and its impact on outcomes within treatment groups.
RESULTS: Among 7496 patients, index treatment distributions were 56.6 % PDE5i, 25.9 % ERA, 6.6 % PPA injectable, 4.7 % PPA inhaled, 3.3 % PPA oral, and 2.9 % sGC stimulators. Mean PDC was high across all treatment groups (>90 %); non-adherence was highest with PDE5i (17.0 %) and inhaled PPA (15.3 %). Factors associated with non-adherence varied by drug class. Non-adherence was significantly associated with worse clinical outcomes: in the PDE5i group, risk of mortality more than doubled with non-adherence (HR 2.33 [95 % CI 1.79-3.03]; p < 0.001), and increased more than fivefold in the ERA group (5.43 [3.33-8.85]; p < 0.001).
CONCLUSIONS: Non-adherence to PAH therapy is associated with poor clinical outcomes. Strategies to improve adherence are crucial to optimizing patient outcomes.
OBJECTIVE: Exploring adherence to PAH-specific therapies across therapeutic classes, we identified factors associated with non-adherence and evaluated its impact on clinical outcomes.
METHODS: Using claims from the Komodo Research Database, we identified patients initiating therapy with phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) stimulators, or prostacyclin pathway agents (PPA) between January 2017 and June 2022. Adherence was measured by proportion of days covered (PDC) during the treatment period, defined as 60 days after first therapy until treatment discontinuation/censor. Non-adherence was defined as PDC <80 %. Clinical outcomes were assessed during the treatment period. Stepwise Cox proportional-hazard models identified predictors of non-adherence and its impact on outcomes within treatment groups.
RESULTS: Among 7496 patients, index treatment distributions were 56.6 % PDE5i, 25.9 % ERA, 6.6 % PPA injectable, 4.7 % PPA inhaled, 3.3 % PPA oral, and 2.9 % sGC stimulators. Mean PDC was high across all treatment groups (>90 %); non-adherence was highest with PDE5i (17.0 %) and inhaled PPA (15.3 %). Factors associated with non-adherence varied by drug class. Non-adherence was significantly associated with worse clinical outcomes: in the PDE5i group, risk of mortality more than doubled with non-adherence (HR 2.33 [95 % CI 1.79-3.03]; p < 0.001), and increased more than fivefold in the ERA group (5.43 [3.33-8.85]; p < 0.001).
CONCLUSIONS: Non-adherence to PAH therapy is associated with poor clinical outcomes. Strategies to improve adherence are crucial to optimizing patient outcomes.